Damien McDonald
Damien McDonald's purchase track record
Damien McDonald has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/4/2026 | ENOV | $250K | pending | pending | — |
| 9/11/2025 | ENOV | $200K | -11.9% | -25.9% | +1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
LivaNova Shares Rise on Barclays Overweight Rating. Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.
Transaction History
| ENOV | ▲ Buy | Open Market | 13,035 | $250K | 9/4/2026 | View on chart |
| ENOV | ▼ Sell | Tax Withholding | 12,634 | $328K | 5/12/2026 | View on chart |
| ENOV | ▲ Buy | Grant | 143,923 | $0 | 3/9/2026 | View on chart |
| ENOV | ▲ Buy | Open Market | 6,457 | $200K | 9/11/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 96,296 | $0 | 5/12/2025 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 4,571 | $0 | 3/30/2023 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 2,149 | $92K | 3/30/2023 | View on chart |
| LIVN | ▼ Sell | Open Market | 2,220 | $94K | 3/30/2023 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 3,213 | $0 | 3/30/2023 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 1,511 | $65K | 3/30/2023 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 8,607 | $0 | 3/30/2023 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 4,046 | $173K | 3/30/2023 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 5,119 | $0 | 3/30/2023 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 2,406 | $103K | 3/30/2023 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 25,131 | $0 | 2/27/2023 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 11,812 | $567K | 2/27/2023 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 10,569 | $0 | 2/27/2023 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 4,968 | $238K | 2/27/2023 | View on chart |
| LIVN | ▼ Sell | Open Market | 2,220 | $121K | 12/15/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 3,213 | $0 | 3/30/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 1,511 | $123K | 3/30/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 8,607 | $0 | 3/30/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 4,046 | $330K | 3/30/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 5,120 | $0 | 3/30/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 2,407 | $196K | 3/30/2022 | View on chart |
| LIVN | ▼ Sell | Open Market | 2,784 | $227K | 3/29/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 3,182 | $0 | 3/15/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 1,496 | $109K | 3/15/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 2,429 | $188K | 3/1/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 5,167 | $0 | 3/1/2022 | View on chart |
| LIVN | ▼ Sell | Open Market | 2,784 | $227K | 12/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Enovis joins AAOS Registry Program as industry sponsor
Enovis has become the first multi-registry industry sponsor of the AAOS Registry Program. This move highlights the company's engagement with major orthopedic data initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $38.33.
Enovis joins AAOS Registry Program as industry sponsor. Enovis has become the first multi-registry industry sponsor of the AAOS Registry Program. This move highlights the company's engagement with major orthopedic data initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $38.33.